Med. praxi. 2012;9(4):189-193

Biological treatment of multiple sclerosis

MUDr.Jiří Pi»ha
MS centrum při Neurologickém oddělení KZ a. s. &ndash, Nemocnice Teplice o. z.

Multiple sclerosis is the most common chronic neurological disease affecting young people. The mechanism of autoimmune disease involving

inflammation and degeneration neuroaxonal. Treatment should be initiated in the early stages of disease. Drugs of first choice are beta

interferon or glatirameracetat. In some patients there are signs of intolerance or ineffectiveness of these drugs with the need for change in

therapeutic strategy. Natalizumab is the first monoclonal antibody, which was introduced in multiple sclerosis in medical practice. Other biological

drugs that have a perspective in the treatment of multiple sclerosis, is alemtuzumab, daclizumab and CD20 molecule antagonists.

Keywords: multiple sclerosis, monoclonal antibodies, natalizumab, alemtuzumab, daclizumab, rituximab, ocreluzimab

Published: April 25, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pi»ha J. Biological treatment of multiple sclerosis. Med. praxi. 2012;9(4):189-193.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Havrdová E. Roztrouąená skleróza. Minimonografie. Česk Slov Neurol Neurochir 2008; 71/104(2): 121-132.
    2. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010. Revisions to the McDonald criteria. Ann Neurol. 2011; 69(2): 292-302.
    3. Bruce JM, Lynch SG. Multiple sclerosis: MS treatment adherence-how to keep patients on medication? Nat Rev Neurol. 2011; 7(8): 421-422. Go to original source... Go to PubMed...
    4. Taláb R. Natalizumab. Remedia 2007; 17: 533-541. Go to original source...
    5. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 899-910. Go to original source... Go to PubMed...
    6. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon ?-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 911-923. Go to original source... Go to PubMed...
    7. Goodman AD, Rossman H, Bar-Or A. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009; 72(9): 806-812. Go to original source... Go to PubMed...
    8. Kappos L, Bates D, Edan G. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10(8): 745-758. Go to original source... Go to PubMed...
    9. Horáková D, Havrdová E. Protilátky proti JC viru a stratifikace rizika progresivní multifokální leukoencefalopatie u pacientů s roztrouąenou sklerózou. Doporučení k pouľití nového testu STRATIFY JCVTM. Neurol. praxi 2011; 12: 364-365.
    10. Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol. 2012; 142(1): 9-14. Go to original source... Go to PubMed...
    11. Multiple sclerosis trust: Information, education, reseach and support. Dostupné z url: http://www.mstrust.org.uk/research/drugsindevelopment/alemtuzumab.jsp.
    12. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358(7): 676-688. Go to original source... Go to PubMed...
    13. Kappos L, Li D, Calabresi PA, O'Connor P, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011; 378(9805): 1779-1787. Go to original source... Go to PubMed...
    14. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010; 67(4): 452-461. Go to original source... Go to PubMed...
    15. Fontoura P. Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges. MAbs. 2010; 2(6): 670-681. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.